LC-MS/MS法测定人血浆中氨氯地平的浓度

为了快速、准确地检测人血浆中氨氯地平的浓度,建立了高效液相色谱-质谱联用检测方法。选用Eclipse XDB-C₁₈色谱柱,以甲醇-1 mM乙酸铵溶液-0.1%甲酸溶液为流动相,采用梯度洗脱方法进行分离,样品经乙腈沉淀后进样,选用3200Q-trap型质谱仪的多重反应监测（MRM）扫描方式进行检测。氨氯地平线性范围为0.100~20.000 μg/L,定量下限为0.100 μg/L 。准确度与精密度结果显示：方法日间、日内变异均小于15%,相对偏差为-3.85%~1.94%,低、中、高3个浓度提取回收率为94.90%~97.84%,稳定性好。该方法专属性强、样品处理简便、灵敏度高,可用于人体氨氯地平血药浓度的测定及其制剂的人体药代动力学研究。     

LC-MS/MS法测定人血浆中辛伐他汀浓度

为了建立高效液相色谱-质谱联用法测定人血浆中辛伐他汀浓度的方法,选用Ultimate XB-C₁₈柱（2.1 m×100 mm,3 μm）,以V（甲醇）：V（乙腈）∶V（2.5 mmol/L乙酸铵）=45∶50∶5的溶液为流动相,样品用沉淀蛋白法处理后进样,流速为0.3 mL/min。选用Finnigan TSQ Quantum Access液质联用（LC-MS/MS）分析仪的选择反应监测（SRM）扫描方式进行监测,选择电喷雾离子源ESI,正离子方式。辛伐他汀的线性范围为0.1～20 μg/L,定量下线为0.1 μg/L。准确度与精密度结果显示,方法日间、日内相对标准偏差（RSD）小于15%,方法提取回收率为71.96%～78.44%。稳定性试验中,血浆中辛伐他汀在各种储存条件下均较稳定。试验表明,该方法快速、灵敏,专属性强、重现性好,可用于人血浆中辛伐他汀浓度的测定和药代动力学研究。     

液相色谱-串联质谱法测定人血浆中克林霉素

建立了测定人血浆中克林霉素的LC-MS/MS法。血浆样本用乙腈沉淀蛋白后,选用Shim-pack VP-ODS色谱柱（150 mm ×2.0 mm×5 μm）,以 V(甲醇)∶V(10 mmol•L^-1乙酸铵（含0.25%甲酸）)=55∶45为流动相,流速为0.4 mL•min^-1。选用API3200型三重四极杆串联质谱仪的多重反应监测（MRM）扫描方式进行监测,电喷雾离子化源,正离子方式,选择监测离子反应分别为 m/z 425.2→126.3（克林霉素）和 m/z 256.2→167.3（内标苯海拉明）。克林霉素和苯海拉明的保留时间分别为1.77 min和1.79 min;血浆中克林霉素的线性范围为0.030 0~10.0 mg•L^-1（r>0.99）,定量下限为0.030 0 mg•L^-1;日内、日间相对标准差（RSD）均小于6%;相对偏差（RE）均在±6%的范围以内;平均提取回收率为（101.1± 2.6）%;稳定性试验中,血浆中克林霉素在各种贮存条件下均较稳定。该方法快速、灵敏、专属性强、重现性好,适用于人体内克林霉素的药代动力学研究。     

LC-MS/MS���ⶨ��Ѫ�����׸�����Ũ��

??????Ч??????????????÷????????????????????????Kromasil-C₁₈ ???????50mm??4.6mm??5??m??????V(????):V(0.1%????)=75??25??1mmol•L^-1??????????????????????????з???????ó???????????????????3200QTrap?????????????????????????????MRM????跽????м????????ε??????Χ?3.0~3000.0??g•L^-1???????????3.0??g•L^-1?????????????????????????????????С??15%????????-1.40%~2.07%??????????????????98.2??7.6??%????????á??÷????????????????????????????????????????????????????????????????????о???     

液相色谱-串联质谱法测定人体血浆和尿液中必特螺旋霉素时的基质效应

近年来,人们在使用LC-MS/MS法对生物样品进行高通量分析时发现了基质效应,即被测物的质谱反应信号可以被生物基质增强或抑制,不论是增强或抑制都会影响最终定量结果的准确性[1～3].     

LC-MS/MS法定量测定人血浆中CPRC-127血药浓度

A sensitive liquid chromatography-electrospray ionization-tandem mass spectrometric(LC-MS/MS) method for the determination of CPRC-127 in human plasma was developed and validated. The plasma was extracted using a liquid-liquid phase extraction(LLE), and the sample extract was injected onto the LC-MS/MS system. The limit of quantitation(LLOQ) for CPRC-127 is 0.5 μg•L^－1. This method allows the reproducible and accurate quantification with the concentration range of 0.5-1 000 μg•L^－1. This method can be applied to the quantitation of CPRC-127 in human plasma.     

LC-MS/MS法测定大鼠血浆中MTP-131

MTP-131 is a tetrapeptide under development for treating diabetes. MTP-131 contains a lysine, an arginine, a phenylalanine and a modified tyrosine in its structure. The quantification of MTP-131 in rat plasma was developed and validated by liquid chromatography-tandem mass spectrometry(LC-MS/MS). MTP-131 was separated from plasma by Waters Oasis^® HLB cartridge solid phase extraction, then separated by C₁₈ column. The mobile phase consisted of V(acetonitrile):V(10 mmol L^－1 ammonium acetate):V(acetic acid)＝30:70:0.04. A mass spectrometer equipped with electrospray ionization source was used as a detector and operated in the positive ion mode. Selected reaction monitoring(SRM) using the double protonated molecules of [M＋2H]^2＋ for MTP-131, three main fragment ions of m/z 70, 84, 20 were used for the quantification. The d5-MTP-131 was used as the internal standard. The method exhibites a linear range of 1.0-10 000μg L^－1 for MTP-131 with a lower limit of quantification at 1.0 μg L^－1. The intra- and inter-assay precisions are below 9.9%, and relative errors within 6.0%. The mean extraction recovery of MTP-131 is above 80%. Under the selected chromatographic conditions and sample preparation conditions, there is no significant matrix effect of MTP-131 at low or high concentrations. The validated method proves to be sensitive, rapid, and is applied successfully for the pharmacokinetic study of MTP-131 in rat.     

LC-MS/MS法测定犬血浆中脂质纳米粒10-羟基喜树碱浓度

10-hydroxycamptothecin，camptothecin analogue，is an antitumor agent that targets the nuclear enzyme topoisomerase I. 10-hydroxycamptothecin is injected by sodium salt form in clinic, and myelosuppression is the major toxicity. To enhance water solubility and reduce the toxicity, lipid nanoparticle which is water-soluble was designed. The quantitative analyses of liposomal and total 10-hydroxycamptothecin in dog plasma were developed and validated by liquid chromatographic-tandem mass spectrometry(LC-MS/MS). Two preparation procedures were developed to separate liposomal 10-hydroxycamptothecin, one was solid phase extraction, the other was liquid-liquid extraction. The analyte and internal standand(camptothecin) were separated on a Zorbax SB-C₁₈ column using the mobile phase consisting of V(acetonitrile):V(water):V(formic acid)＝70:30:0.2. Electropray ionization source of MS was applied and operated in positive ion mode. The peak area of the m/z 365→321 transition of 10-hydroxycamptothecin and that of m/z 349→305 transition of the IS were measured. The linear calibration curve for liposmal 10-hydroxycamptothecin is obtained in the concentration range of 1.00- 1 000μg L^－1, and that for total 10-hydroxycamptothecin is obtained in the concentration range of 1.00- 2 000μg L－1. The recoveries of solid phase extraction and liquid-liquid extraction methods are 48.1%-52.4% and 79.6%-83.0%, respectively. This validated LC-MS/MS assay is successfully applied to pharmacokinetic study of 10-hydroxycamptothecin loaded lipid nanoparticle in dogs after administration single dosages of 0.5, 1, 2 mg kg^－1 and multiple dosage of 1.0 mg kg^－1 d^－1 10-hydroxycamptothecin lipid nanoparticle.     

LC-MS/MS法测定比格犬血浆中氯吡格雷活性代谢物

建立了一种定量测定比格犬血浆中氯吡格雷活性代谢物（active metabolize, AM）的液相色谱-串联质谱（LC-MS/MS）法。采血管中加入酯酶抑制剂敌敌畏,采样后立即离心处理,取上层血浆,加入2-溴-3’-甲氧基苯乙酮（MPB）进行衍生化,反应完成后直接加入含0.1%甲酸的冰乙腈沉淀蛋白,取上清液,测定氯吡格雷活性代谢物的衍生化产物（MP-AM）。以乙腈0.1%甲酸为流动相,梯度洗脱,API4000电喷雾离子源,多反应监测（MRM）模式扫描。在优化的实验条件下,获得了峰宽较窄且对称的色谱峰;MP-AM的线性范围为1~1 000 μg/L,相关系数大于0.995;生物基质效应较小,提取回收率在92.8%~95.1%之间,相对标准偏差小于8.27%。该方法的准确度和精密度均符合国家食品药品监督管理总局（China Food and Drug Administration, CFDA）的相关要求,适用于比格犬血浆中氯吡格雷的药代动力学研究。     

LC-MS/MS法测定人全血中环孢素A浓度及环孢素眼用乳剂健康人体药代动力学研究

建立液相色谱 质谱联用法测定人全血中环孢素A浓度,选用Kromasil-C₁₈色谱柱（20 mm×4.6 mm×5 μm）,以甲醇1 mmol•L^-1甲酸铵溶液为流动相,采用梯度洗脱进行分离,样品用沉淀蛋白法处理后进样,流速1.1 mL•min^-1,柱温60 ℃,进样量20 μL。选用3200 QTrap型三重四极杆串联质谱仪的多重反应监测（MRM）扫描方式进行检测。环孢素A的线性范围为0.2~20.00 μg•L^-1,定量下限为0.2 μg•L^-1。准确度与精密度结果显示,方法日间、日内变异均小于15%,相对偏差为-12.60%~12.80%,方法提取回收率为（98.1±4.7）%,稳定性较好。所建立的方法快速、灵敏、专属性强、重现性好,可用于环孢素眼用乳剂健康人体药代动力学研究。